The COVID-19 pandemic puts both public health systems and the public at large to an excruciating test. There is an urgent need for governments and the citizens they represent to heed the advice of experts to help slow the spread of the disease and ease the enormous burden being placed on hospitals and healthcare workers around the world. Elsewhere, the pharmaceutical industry and public research institutes continue to search for a vaccine and effective therapies against COVID-19. It is of the utmost importance that the end products of this work be accessible and affordable for everyone, wherever they live.
Meanwhile, around the world, and particularly in low- and middle-income countries, the unintended consequences of social distancing and lockdown of services wreaks havoc for the poorest and disenfranchised. Reports of avoidable deaths as a direct result of restrictions in place, or the potential disruption to essential supplies of life-saving medicines, such as insulin are likely to become more common, as attention is focused almost solely on beating COVID-19. For that reason, HAI’s core work on medicines supply chains, Sexual and Reproductive Health and Rights (SRHR), snakebite, insulin and access to medicines in Europe continue, with a stronger emphasis and reflection on the impact of COVID-19 on all of our projects.
On this page, you will find more information about the work HAI is doing to help ensure the affordability and accessibility of treatments for COVID-19, as well as the impact and mitigation of challenges related to all our programmes.